Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive‑stage small cell lung cancer: A case report and literature review

Xu,Nengwen; Fan,Zhimin; Liu,Weie; Zhang,Cangjian; Zhang,Junyu; Li,Linjie

doi:10.3892/ol.2022.13579

Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive‑stage small cell lung cancer: A case report and literature review

Authors:
- Nengwen Xu
- Zhimin Fan
- Weie Liu
- Cangjian Zhang
- Junyu Zhang
- Linjie Li
View Affiliations

Affiliations: Department of Hematology, College of Medicine, Lishui Hospital, Zhejiang University, Lishui, Zhejiang 323000, P.R. China
Published online on: November 2, 2022 https://doi.org/10.3892/ol.2022.13579
Article Number: 459
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mantle cell lymphoma (MCL) is a B‑cell non‑Hodgkin lymphoma with an advanced stage; it occurs frequently and affects the lymph nodes, spleen, blood and bone marrow. The synchronous occurrence of MCL bone marrow involvement (MCLBMI) and malignant tumors is extremely rare. To the best of our knowledge, synchronous extensive‑stage small cell lung cancer (ES‑SCLC) and MCLBMI have not been previously reported. In the present study, a rare case of ES‑SCLC with synchronous MCLBMI is reported in a 59‑year‑old man. The patient received cisplatin, etoposide, dexamethasone and rituximab chemotherapy for the treatment of both malignancies. The follow‑up computed tomography scan disclosed regression of the left upper lobe mass and the routine blood test indicated that the platelet count was gradually increasing to normal levels. Following therapy, the patient achieved a partial response. The experience in this case report indicated that the treatment of synchronous SCLC and MCLBMI requires consideration of the respective patient clinical features, biological behavior and cumulative toxicity of the treatment regimens administered for both malignant tumors. The present study demonstrated that thrombocytopenia was not a chemotherapy contraindication, thus providing a new treatment option for this type of patient.

View Figures

View References

1	Karthikeyan VS, Sistla SC, Srinivasan R, Basu D, Panicker LC, Ali SM and Rajkumar N: Metachronous multiple primary malignant neoplasms of the stomach and the breast: Report of two cases with review of literature. Int Surg. 99:52–55. 2014. View Article : Google Scholar : PubMed/NCBI
2	Fujii M, Shirai T, Asada K, Saito Y, Hirose M and Suda T: Synchronous diffuse large B-cell lymphoma and squamous cell lung carcinoma. Respirol Case Rep. 2:33–35. 2014. View Article : Google Scholar : PubMed/NCBI
3	Vose JM: Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 90:739–745. 2015. View Article : Google Scholar : PubMed/NCBI
4	Bernhardt EB and Jalal SI: Small cell lung cancer. Cancer Treat Res. 170:301–322. 2016. View Article : Google Scholar : PubMed/NCBI
5	Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group and Eastern Cooperative Oncology Group, ; et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
6	Cheson BD: Staging and response assessment in lymphomas: The new Lugano classification. Chin Clin Oncol. 4:52015.PubMed/NCBI
7	Lee TK, Myers RT, Scharyj M and Marshall RB: Multiple primary malignant tumors (MPMT): Study of 68 autopsy cases (1963–1980). J Am Geriatr Soc. 30:744–753. 1982. View Article : Google Scholar : PubMed/NCBI
8	Henne T and Schmähl D: Occurrence of second primary malignancies in man-a second look. Cancer Treat Rev. 12:77–94. 1985. View Article : Google Scholar : PubMed/NCBI
9	Roy SD, Stafford JA, Scally J and Selvachandran SN: A rare case of breast carcinoma co-existing with axillary mantle cell lymphoma. World J Surg Oncol. 1:272003. View Article : Google Scholar : PubMed/NCBI
10	Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, et al: Cancer survivorship-genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst. 98:15–25. 2006. View Article : Google Scholar : PubMed/NCBI
11	Park SL, Caberto CP, Lin Y, Goodloe RJ, Dumitrescu L, Love SA, Matise TC, Hindorff LA, Fowke JH, Schumacher FR, et al: Association of cancer susceptibility variants with risk of multiple primary cancers: the population architecture using genomics and epidemiology study. Cancer Epidemiol Biomarkers Prev. 23:2568–2578. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chien SH, Liu CJ, Hong YC, Teng CJ, Hu YW, Ku FC, Yeh CM, Chiou TJ, Gau JP and Tzeng CH: Development of second primary malignancy in patients with non- Hodgkin lymphoma: A nationwide population-based study. J Cancer Res Clin Oncol. 141:1995–2004. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kim YJ, Shin HJ, Won CH, Chang SE, Lee MW, Choi JH and Lee WJ: The incidence of other primary cancers in patients with cutaneous lymphoma. Ann Dermatol. 30:335–341. 2018. View Article : Google Scholar : PubMed/NCBI
14	Alakeel F, Lee E, Baird-Howell M and Easley S: Synchronous ductal carcinoma in situ and intravascular large B-cell lymphoma of the breast. Appl Immunohistochem Mol Morphol. 27:e91–e92. 2019. View Article : Google Scholar : PubMed/NCBI
15	Li J, Zhou C, Liu W, Sun X and Meng X: Synchronous diffuse large B cell lymphoma of the stomach and small cell lung carcinoma: A case report. Medicine (Baltimore). 96:e88732017. View Article : Google Scholar : PubMed/NCBI
16	Bermejo JL, Pukkala E, Johannesen TB, Sundquist J and Hemminki K: Age time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden. Br J Haematol. 164:675–683. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ibrahim EM, Kazkaz GA, Abouelkhair KM, Al-Mansour MM, Al-Fayea TM, Al-Foheidi M, Bayer AM and Elmasri OA: Increased risk of second lung cancer in Hodgkin's lymphoma survivors: A meta-analysis. Lung. 191:117–134. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kampalath B, Abed N, Chitambar CR, Vantuinen P, Chakrabarty G, Hanson G, Rao RN, Shidham VB and Chang CC: Mantle cell lymphoma in lymph nodes with metastatic small cell carcinoma of lung: A diagnostic and treatment dilemma. Leuk Lymphoma. 45:409–414. 2004. View Article : Google Scholar : PubMed/NCBI
19	Argiris A and Murren JR: Staging and clinical prognostic factors for small-cell lung cancer. Cancer J. 7:437–447. 2001.PubMed/NCBI
20	Loscocco GG, Piccini M, Bencini S and Vergoni F: Bone marrow involvement in small cell lung cancer. Hematol Transfus Cell Ther. 43:543–544. 2021. View Article : Google Scholar : PubMed/NCBI
21	Pasini F, Cetto GL and Pelosi G: Does bone marrow involvement affect prognosis in small-cell lung cancer? Ann Oncol. 9:247–250. 1998. View Article : Google Scholar : PubMed/NCBI
22	Brennan P, Scélo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, et al: Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer. 93:159–166. 2005. View Article : Google Scholar : PubMed/NCBI
23	Fonseca D, Musthyala B, Ahmed F, Murthy SS and Raju KVVN: A tale of synchronous lung carcinoma and diffuse large B-cell lymphoma of ileum:a rare combination. Lung India. 32:398–401. 2015. View Article : Google Scholar : PubMed/NCBI
24	Tokuchi Y, Kamachi M, Harada M, Hasegawa M, Mishina T, Yamashiro K, Suzuki H and Isobe H: Synchronous triple lung cancers after treatment for non-Hodgkin's lymphoma:metachronous quadruple cancers. Intern Med. 42:1031–1034. 2003. View Article : Google Scholar : PubMed/NCBI
25	André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, Tilly H, Coiffier B, Bosly A, Morel P, et al: Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood. 103:1222–1228. 2004. View Article : Google Scholar : PubMed/NCBI
26	Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M and Kluin-Nelemans HC: Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma;an EORTC cohort study. Haematologica. 91:1481–1488. 2006.PubMed/NCBI
27	Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge O, Fosså A, Kolstad A, Loge JH, et al: A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. Br J Haematol. 173:432–443. 2016. View Article : Google Scholar : PubMed/NCBI
28	Mersheimer WL, Ringel A and Eisenberg H: Some characteristics of multiple primary cancers. Ann NY Acad Sci. 114:896–921. 1964. View Article : Google Scholar
29	Cybulski C, Nazarali S and Narod SA: Multiple primary cancers as a guide to heritability. Int J Cancer. 135:1756–1763. 2014. View Article : Google Scholar : PubMed/NCBI
30	Rivera B, Castellsagué E, Bah I, van Kempen LC and Foulkes WD: Biallelic NTHL1 mutations in a woman with multiple primary tumors. N Engl J Med. 373:1985–1986. 2015. View Article : Google Scholar : PubMed/NCBI
31	Luo YH, Ho HL, Tsai CM, Shih JF, Chiu CH, Lai SL, Lee YC, Perng RP, Whang-Peng J, Chou TY and Chen YM: The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs. Am J Clin Oncol. 38:147–151. 2015. View Article : Google Scholar : PubMed/NCBI
32	Aqeel M, Uysal-Biggs N, Fenske TS and Rao N: one pulmonary lesion, 2 synchronous malignancies. J Investig Med High Impact Case Rep. 6:23247096187859342018.PubMed/NCBI
33	Hatzibougias D, Bobos M, Karayannopoulou G, Karkavelas G, Karapanagiotidis GT, Foroulis CN and Kostopoulos I: A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura. World J Surg Oncol. 6:1372008. View Article : Google Scholar : PubMed/NCBI
34	Kai K, Ryu Y, Kamochi K, Nishioka A, Kubota Y, Nakamura M, Kimura S, Sueoka E and Aishima S: Synchronous mantle cell lymphoma and lung adenocarcinoma presenting in a pleural effusion: A rare tumor combination and a potential pitfall of cytodiagnosis. Cytopathology. 29:400–402. 2018. View Article : Google Scholar : PubMed/NCBI
35	Samuel G, Simoff M, Chaabaan S and Diaz-Mendoza J: Synchronic diagnosis of non-hodgkin lymphoma and lung adenocarcinoma via EBUS-guided TBNA. J Bronchology Interv Pulmonol. 25:e41–e42. 2018. View Article : Google Scholar : PubMed/NCBI
36	Braham E, Zarrouk M, Mlika M, Kilani T and El Mezni F: Synchronous mantle cell lymph node lymphoma and pulmonary adenocarcinoma: A case report with literature review. Clin Respir J. 11:430–432. 2017. View Article : Google Scholar : PubMed/NCBI
37	Craig FE and Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 111:3941–3967. 2008. View Article : Google Scholar : PubMed/NCBI